Reinvigoron TheraTech Revenue
Biotechnology Research • • 1-10 Employees
Reinvigoron TheraTech revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Key Contact at Reinvigoron TheraTech
Kejin Zhou
Founder
Company overview
| Headquarters | XX |
| NAICS | 541714 |
| Employees | 1-10 |
About Reinvigoron TheraTech
Reinvigoron is a biotechnology company creating systemically-delivered, non-viral DNA therapeutics to treat resistant cancers. To outsmart cancer, we need therapies that combine optimal delivery, exquisite specificity, modularity, and scalable manufacturing. We are pioneering therapeutics that work intracellularly to reprogram cancer cells into biologic drug factories. Using our proprietary technology, we deliver therapeutic genes via tiny nanoparticle carriers - akin to a microscopic trojan horse - that only activate in cancer cells. We are not just targeting cancer; we are transforming it, unlocking the potential to turn the disease against itself and redefine what’s possible in cancer treatment.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Reinvigoron TheraTech has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Reinvigoron TheraTech has never raised funding before.
Canada
Norway
Israel
Australia
South AfricaFrequently asked questions
4.8
40,000 users
